| 纯度 | >85% SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK3 |
| Uniprot No | Q00526 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-305aa |
| 氨基酸序列 | MDMFQKVEKIGEGTYGVVYKAKNRETGQLVALKKIRLDLEMEGVPSTAIREISLLKELKHPNIVRLLDVVHNERKLYLVFEFLSQDLKKYMDSTPGSELPLHLIKSYLFQLLQGVSFCHSHRVIHRDLKPQNLLINELGAIKLADFGLARAFGVPLRTYTHEVVTLWYRAPEILLGSKFYTTAVDIWSIGCIFAEMVTRKALFPGDSEIDQLFRIFRMLGTPSEDTWPGVTQLPDYKGSFPKWTRKGLEEIVPNLEPEGRDLLMQLLQYDPSQRITAKTALAHPYFSSPEPSPAARQYVLQRFRH |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK3重组蛋白的模拟参考文献示例(注：部分内容为学术推测，实际文献需通过数据库验证)：
1. **"CDK3: A Novel Cyclin-Dependent Kinase Involved in Cell Cycle Regulation"**
*Meyerson M, Harlow E.*
摘要：该研究首次报道了CDK3的克隆与重组表达，证实其与Cyclin C结合并具有激酶活性，在G1/S期调控中可能通过磷酸化Rb蛋白促进细胞周期进程。
2. **"Recombinant CDK3 Protein: Purification and Functional Characterization"**
*Ren S, Rollins BJ.*
摘要：通过大肠杆菌系统成功表达并纯化重组CDK3蛋白，体外实验证明其依赖Cyclin C激活，并对转录因子E2F1具有调控作用，为后续靶向药物筛选奠定基础。
3. **"CDK3-Cyclin E Interaction and Its Role in Cellular Transformation"**
*Ye D, et al.*
摘要：利用重组CDK3/Cyclin E复合物进行结构分析，揭示其在癌细胞中异常激活的机制，并通过激酶抑制实验验证其在肿瘤增殖中的潜在治疗靶点价值。
4. **"Development of a CDK3-Specific Inhibitor Using Recombinant Kinase Assays"**
*Zhang X, et al.*
摘要：基于重组CDK3蛋白的高通量筛选平台鉴定出小分子抑制剂CP-321.可选择性阻断CDK3活性并抑制黑色素瘤细胞的体外侵袭能力。
**注意**：以上为模拟文献，实际研究需查阅PubMed、Web of Science等平台。CDK3研究相对较少，建议结合关键词“CDK3 recombinant protein”“kinase activity”进一步检索。
**Background of CDK3 Recombinant Protein**
CDK3 (cyclin-dependent kinase 3) is a member of the cyclin-dependent kinase family, which plays pivotal roles in cell cycle regulation and transcriptional control. Structurally, CDK3 shares homology with other CDKs, featuring a conserved serine/threonine kinase domain. Its activity is tightly regulated by binding to specific cyclins (e.g., cyclin C) and phosphorylation events. CDK3 is implicated in facilitating the G1-to-S phase transition by phosphorylating retinoblastoma (Rb) protein, thereby releasing E2F transcription factors to drive S-phase entry. However, its biological significance remains less characterized compared to CDK2 or CDK1. partly due to overlapping functions and low expression in certain tissues.
Recombinant CDK3 protein is engineered using heterologous expression systems (e.g., *E. coli* or insect cells*) to produce highly purified, functional kinase for *in vitro* studies. This tool enables researchers to investigate CDK3’s enzymatic activity, substrate specificity, and interactions with cyclins or inhibitors. Its applications span mechanistic studies of cell cycle dysregulation, cancer research (e.g., exploring CDK3 overexpression in tumors), and drug discovery efforts targeting CDK family members.
Despite limited physiological data, CDK3 has gained attention for its potential role in oncogenesis and neuronal development. Recent studies suggest its involvement in Ras-mediated senescence bypass and transcriptional regulation via non-cyclin partners. However, challenges persist in distinguishing CDK3-specific functions from those of other CDKs, necessitating precise biochemical tools like recombinant CDK3. Ongoing research aims to clarify its pathophysiological relevance and assess its viability as a therapeutic target in cancers or neurodegenerative disorders.
×
